版本:
中国

BRIEF-Capricor Therapeutics provides update on ALLSTAR trial

May 12 Capricor Therapeutics Inc:

* Capricor Therapeutics provides update on allstar trial

* Capricor Therapeutics Inc - ALLSTAR trial unlikely to achieve primary efficacy endpoint of change in infarct size in patients following heart attack

* Capricor Therapeutics- pre-specified administrative interim analysis demonstrated a low probability of achieving statistically-significant difference

* Capricor Therapeutics Inc - there were no safety signals in cap-1002 treatment cohort

* Capricor Therapeutics - plans to reduce scope of operations, including size of workforce, in order to focus financial resources primarily on DMD program

* Capricor Therapeutics-to initiate enrollment into randomized,double-blind, placebo-controlled, clinical trial of intravenous CAP-1002 in DMD in H2 2017 Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐